logo-loader
RNS
viewe-Therapeutics plc

Holding(s) in Company

/**/ sup{font-size:80%}link{ color: #000000 }visited{ color: fuchsia } .l{size:612.0pt 792.0pt;margin:72.0pt 3.0cm 72.0pt 53.85pt;}div.l{}p.fc{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;border:none;background:white}span.fa{font-size: 10.0pt;font-family:"Arial","sans-serif";color:windowtext}table.fd{margin-left:1.4pt;border-collapse:collapse;border:none}tr.et{height:13.1pt}td.ew{width:202.95pt;border:none;padding: 4.0pt 4.0pt 4.0pt 4.0pt;height:13.1pt}p.fe{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;border:none; font-weight: bold}span.ey{font-size:9.0pt;font-family:"Arial","sans-serif";color:windowtext}td.eu{width:248.85pt;border:none;padding: 4.0pt 4.0pt 4.0pt 4.0pt;height:13.1pt} span.ev{color:windowtext}tr.er{height:11.65pt}td.es{width:459.8pt;border:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:11.65pt}tr.eo{height:17.5pt}td.ep{width:459.8pt;border:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:17.5pt}span.eq{font-family:"Arial","sans-serif";color:windowtext}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;border:none;}span.em{font-size:10.0pt;font-family:"Arial","sans-serif"}tr.eg{height:40.6pt}td.ej{width:252.35pt;border:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:40.6pt} span.el{font-size:11.0pt;font-family: "Arial","sans-serif"}span.ek{font-size:11.0pt;font-family:"Arial","sans-serif"}td.eh{width:204.7pt;border:solid black 1.0pt;border-left:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:40.6pt}p.ff{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;border:none;text-align: center}tr.ee{height:14.0pt}td.ef{width:459.8pt;border:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:14.0pt}tr.dz{height:20.85pt}td.ed{width:411.2pt;border:solid black 1.0pt; border-top:none;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:20.85pt}td.ea{width:40.6pt;border-top:none;border-left:none;border-bottom: solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:20.85pt}span.ec{font-family:"Trebuchet MS","sans-serif"} span.eb{font-family:"Wingdings 2"}tr.dw{height:22.65pt}td.dy{width:411.2pt;border:solid black 1.0pt; border-top:none;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:22.65pt}td.dx{width:40.6pt;border-top:none;border-left:none;border-bottom: solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:22.65pt}tr.dt{height:19.5pt}td.dv{width:411.2pt;border:solid black 1.0pt; border-top:none;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:19.5pt}td.du{width:40.6pt;border-top:none;border-left:none;border-bottom: solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:19.5pt}td.ds{width:105.4pt;border-top:none;border-left:solid black 1.0pt; border-bottom:solid black 1.0pt;border-right:none;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:19.5pt}td.dr{width:297.8pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:19.5pt}td.dq{border:none} tr.dm{height:27.0pt}td.do{width:249.4pt;border:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:27.0pt}span.dp{font-size:11.0pt; font-family:"Arial","sans-serif"}td.dn{width:202.4pt;border:solid black 1.0pt;border-left:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:27.0pt}tr.di{height:27.75pt}td.dk{width:249.4pt;border:solid black 1.0pt;border-top:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:27.75pt}p.fg{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;border:none;font-weight: bold}td.dj{width:202.4pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:27.75pt}tr.df{height:25.1pt}td.dh{width:249.4pt;border:solid black 1.0pt;border-top:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:25.1pt} td.dg{width:202.4pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:25.1pt}tr.dc{height:22.1pt}td.de{width:249.4pt;border:solid black 1.0pt;border-top:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:22.1pt}td.dd{width:202.4pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:22.1pt}tr.cz{height:27.5pt}td.db{width:249.4pt;border:solid black 1.0pt;border-top:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:27.5pt}td.da{width:202.4pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:27.5pt}tr.cx{height:12.15pt}td.cy{width:465.1pt;border:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:12.15pt}tr.cv{height:15.4pt} td.cw{width:465.1pt;border:solid black 1.0pt; border-top:none;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:15.4pt}tr.co{height:33.15pt}td.cr{width:83.45pt;border:solid black 1.0pt; border-top:none;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:33.15pt}span.cu{font-size:10.0pt;font-family: "Arial","sans-serif"}span.ct{font-size:10.0pt;font-family:"Arial Unicode MS","serif"}span.cs{font-size:10.0pt;font-family: "Arial Unicode MS","serif"}td.cq{width:107.55pt;border-top:none; border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:33.15pt}td.cp{width:258.1pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:33.15pt}tr.ch{height:22.15pt}td.cm{width:50.85pt;border-top:none; border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:22.15pt} span.cn{font-size: 10.0pt;font-family:"Arial Unicode MS","serif"}td.cl{width:48.7pt;border-top:none; border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:22.15pt}td.ck{width:48.7pt;border-top:none;border-left:none;border-bottom: solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:22.15pt}td.cj{width:88.85pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:22.15pt}td.ci{width:104.55pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:22.15pt}td.cg{width:48.7pt;border-top:none;border-left:none;border-bottom: solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:14.0pt}span.cf{font-size: 10.0pt;font-family:"Arial","sans-serif"}td.ce{width:32.15pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:14.0pt}td.cd{width:48.2pt;border-top:none;border-left:none;border-bottom: solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:14.0pt}td.cc{width:48.35pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:14.0pt} tr.bv{height:45.5pt}td.cb{width:83.45pt;border:solid black 1.0pt;border-top:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:45.5pt}td.ca{width:50.85pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:45.5pt}td.bz{width:48.7pt;border-top:none;border-left:none;border-bottom: solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:45.5pt}td.by{width:32.15pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:45.5pt}td.bx{width:48.2pt;border-top:none;border-left:none;border-bottom: solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:45.5pt}td.bw{width:48.35pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:45.5pt}tr.bt{height:19.0pt}td.bu{width:459.8pt;border:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:19.0pt}tr.br{height:18.5pt} td.bs{width:459.8pt;border:solid black 1.0pt; border-top:none;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:18.5pt}tr.bl{height:77.15pt}td.bq{width:102.75pt;border:solid black 1.0pt; border-top:none;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:77.15pt}td.bp{width:66.65pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:77.15pt}td.bo{width:76.4pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:77.15pt}td.bn{width:102.7pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:77.15pt}td.bm{width:79.3pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:77.15pt}tr.bf{height:41.9pt}td.bk{width:102.75pt;border:solid black 1.0pt;border-top:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:41.9pt}td.bj{width:66.65pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:41.9pt} td.bi{width:76.4pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:41.9pt}td.bh{width:102.7pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:41.9pt}td.bg{width:79.3pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:41.9pt}span.be{font-family:"Arial","sans-serif"}tr.bc{height:24.15pt}td.bd{width:465.1pt;border:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:24.15pt}td.bb{width:465.1pt;border:solid black 1.0pt; border-top:none;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:18.5pt}td.ba{width:82.35pt;border:solid black 1.0pt; border-top:none;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:33.15pt}td.az{width:45.8pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:33.15pt}td.ay{width:53.6pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:33.15pt} td.ax{width:64.9pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:33.15pt}td.aw{width:91.15pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:33.15pt}td.av{width:87.3pt;border-top:none; border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:33.15pt}td.au{width:82.35pt;border:solid black 1.0pt; border-top:none;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:22.15pt}td.at{width:45.8pt;border-top:none; border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:22.15pt}td.as{width:53.6pt;border-top:none; border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:22.15pt}td.ar{width:64.9pt;border-top:none; border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:22.15pt}td.aq{width:91.15pt;border-top:none; border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:22.15pt}td.ao{width:43.35pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:22.15pt}p.fh{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;border:none;font-weight: bold; text-align: center} td.an{width:35.8pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:22.15pt}tr.ak{height:17.1pt}td.am{width:43.35pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:17.1pt}td.al{width:35.8pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:17.1pt}tr.ai{height:18.4pt}td.aj{width:459.8pt;border:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:18.4pt}tr.af{height:11.15pt}td.ah{width:249.4pt;border:solid black 1.0pt;border-top:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:11.15pt}td.ag{width:202.4pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:11.15pt}td.ae{width:249.4pt;border:solid black 1.0pt;border-top:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:19.0pt} td.ad{width:202.4pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:19.0pt}tr.aa{height:25.25pt}td.ab{width:459.8pt;border:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:25.25pt}span.ac{font-size:11.0pt; font-family:"Arial Unicode MS","serif"}tr.y{height:99.45pt}td.z{width:459.8pt;border:solid black 1.0pt; border-top:none;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:99.45pt}td.x{width:459.8pt;border:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:12.15pt}td.w{width:249.4pt;border:solid black 1.0pt;border-top:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:18.5pt}td.v{width:202.4pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:18.5pt}tr.s{height:36.5pt} td.u{width:249.4pt;border:solid black 1.0pt;border-top:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:36.5pt}td.t{width:202.4pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:36.5pt}tr.p{height:39.5pt}td.r{width:249.4pt;border:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:39.5pt}td.q{width:202.4pt;border:solid black 1.0pt;border-left:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:39.5pt}span.o{font-size:11.0pt;font-family:"Arial","sans-serif"; color:#393939;background:white}span.m{font-size:10.0pt;font-family:"Arial Unicode MS","serif"; color:black;border:none}br.n{page-break-before:always} /**/
RNS Number : 2436R
e-Therapeutics plc
28 October 2019
 

 

For filings with the FCA include the annex


For filings with issuer exclude the annex



TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i

 

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

e-Therapeutics PLC

 

 

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

 P

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached


An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments


An event changing the breakdown of voting rights


Other (please specify):

 


 

 

3. Full name of person(s) subject to the notification obligation: iii

Ali Mortazavi

4. Full name of shareholder(s)

(if different from 3.): iv


5. Date of the transaction and date on which the threshold is crossed or reached: v

25 October 2019

6. Date on which issuer notified:

27 October 2019

7. Threshold(s) that is/are crossed or

reached: vi, vii

18.0%

 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB00B2823H99

nil

nil

49,000,000

49,000,000

nil

18.2%

nil

 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date xiii

Exercise/
Conversion
Period xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights






 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise
price

Expiration
date xvii

Exercise/
Conversion
period xviii

Number of voting
rights instrument
refers to

% of voting rights xix, xx






Nominal

Delta



 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

49,000,000

18.2%

 

 

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: xxi


 

 

Proxy Voting:

10. Name of the proxy holder:


11. Number of voting rights proxy holder will cease to hold:


12. Date on which proxy holder will cease to hold voting rights:


 

 

13. Additional information:


14. Contact name:

 Ali Mortazavi

15. Contact telephone number:

 0208 56 37609

 

 



 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
HOLEAEEXADXNFAF

Quick facts: e-Therapeutics plc

Price: 3.25

Market: AIM
Market Cap: £8.74 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

RNS

Holding(s) in Company

4 weeks ago

Holding(s) in Company

on 10/29/2019

Holding(s) in Company

on 10/28/2019

Holding(s) in Company

on 10/28/2019

Half-year Report

on 10/07/2019

Holding(s) in Company

on 09/17/2019